Corcept Therapeutics Stock Shines at New All-Time Highs Despite Its Valuation
Corcept Therapeutics (CORT) demonstrates exceptional price momentum with shares up more than 50% over the past year. CORT’s fundamentals are robust with revenue and earnings both projected to grow this year. Technical indicators remain bullish with a 100% “Buy” opinion from Barchart. Analyst sentiment is mixed —ratings range from “Strong...
Barchart ·